The presence of MET activation in a broad range of cell lines (Figure 4C), as well as the association between high MET expression and poor survival (Figure 4B), indicates that MET could be investigated for therapeutic targeting in patients with NB exhibiting similar genomic and proteomic profiles. Here, MET is linked to neuroblastoma.